Experienced in Cholangitis

Dr. Timothy E. Ritter

Gastroenterology | Internal Medicine
505 S Nolan Dr Ste, A, 
Southlake, TX 
38 Years of Experience
Experienced in Cholangitis
505 S Nolan Dr Ste, A, 
Southlake, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Timothy Ritter is an Internal Medicine specialist and a Gastroenterologist in Southlake, Texas. Dr. Ritter has been practicing medicine for over 38 years and is rated as an Experienced provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Ulcerative Colitis, Crohn's Disease, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Texas Southwestern Medical School, 1987
Residency
Internal Medicine, Parkland Memorial Hospital
Specialties
Gastroenterology
Internal Medicine
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine
Fellowships
Gastroenterology, Parkland Memorial Hospital
GI, Parkland Health and Hospital System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Texas Digestive Disease Consultants
505 S Nolan Dr Ste, A, Southlake, TX 76092

Additional Areas of Focus

Dr. Ritter has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn's Disease Risk Prediction Tool
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Other
Study Phase: Phase 4
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Biological
Study Drug: Nexvax2
Study Phase: Phase 2
View 6 Less Clinical Trials

25 Total Publications

Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
Journal: Inflammatory bowel diseases
Published: April 18, 2025
Similar Doctors
Distinguished in Cholangitis
Dr. Tarek Sawas
Gastroenterology
Distinguished in Cholangitis
Dr. Tarek Sawas
Gastroenterology

University Of Texas Southwestern Medical Center At Dallas

1801 Inwood Rd, 
Dallas, TX 
 (17.3 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tarek Sawas is a Gastroenterologist in Dallas, Texas. Dr. Sawas is rated as a Distinguished provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Barrett Esophagus, Cholangitis, Bile Duct Obstruction, Endoscopy, and Gastric Bypass.

Distinguished in Cholangitis
Dr. Paul R. Tarnasky
Gastroenterology
Distinguished in Cholangitis
Dr. Paul R. Tarnasky
Gastroenterology

Texas Digestive Disease Consultants

221 W Colorado Blvd PAV II, Ste 630, 
Dallas, TX 
 (20.1 miles away)
972-449-0540
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Tarnasky is a Gastroenterologist in Dallas, Texas. Dr. Tarnasky is rated as an Elite provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Hereditary Pancreatitis, Acute Pancreatitis, Pancreas Divisum, Endoscopy, and Gastric Bypass.

Distinguished in Cholangitis
Dr. Parvez S. Mantry
Gastroenterology | Hepatology
Distinguished in Cholangitis
Dr. Parvez S. Mantry
Gastroenterology | Hepatology

MedHealth DBA Methodist Transplant Specialists

1411 N Beckley Ave Pavilion III, Ste 268, 
Dallas, TX 
 (22.0 miles away)
972-449-0540
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Parvez Mantry is a Hepatologist and a Gastroenterologist in Dallas, Texas. Dr. Mantry is rated as an Elite provider by MediFind in the treatment of Cholangitis. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Liver Failure, Hepatitis, Liver Transplant, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritter's expertise for a condition
ConditionClose
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile